8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study : Acute effects of the synthetic cannabinoid JWH-018

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <div class="section"> <a class="named-anchor" id="bph14066-sec-0001"> <!-- named anchor --> </a> <h5 class="section-title" id="d661514e244">Background and Purpose</h5> <p id="d661514e246">Synthetic cannabinoids (often sold as Spice or K2) have become a very popular alternative to cannabis due to their easy access and portrayed safety. Controlled studies on the behavioural effects of synthetic cannabinoids are currently lacking, which hampers risk assessments of these compounds. </p> </div><div class="section"> <a class="named-anchor" id="bph14066-sec-0002"> <!-- named anchor --> </a> <h5 class="section-title" id="d661514e249">Experimental Approach</h5> <p id="d661514e251">This is a first attempt to assess the influence of a synthetic cannabinoid, JWH‐018, on neurocognition and subjective experience in humans after controlled administration. JWH‐018, 2 and 3 mg, was administered to six healthy cannabis‐experienced volunteers in a placebo‐controlled, cross‐over study following an escalating dosing schedule. Participants were monitored for 12 h after drug administration, and several neurocognitive measures and subjective questionnaires were taken. </p> </div><div class="section"> <a class="named-anchor" id="bph14066-sec-0003"> <!-- named anchor --> </a> <h5 class="section-title" id="d661514e254">Key Results</h5> <p id="d661514e256">Serum concentrations of JWH‐018 were highest after the 2 mg dose but generally low after administration of both doses. Both doses of JWH‐018 were well tolerated, and no serious side effects were reported. Participants reported feeling more ‘high’ at 1 and 2 h after administration, particularly after the 2 mg dose. Behavioural impairments also emerged despite the low serum concentrations of JWH‐018. The low dose of JWH‐018 impaired performance on the tracking, divided attention and stop signal task. </p> </div><div class="section"> <a class="named-anchor" id="bph14066-sec-0004"> <!-- named anchor --> </a> <h5 class="section-title" id="d661514e259">Conclusion and Implications</h5> <p id="d661514e261">JWH‐018 dosing in the present study resulted in drug concentrations that were generally low and not fully representative of common use. Yet initial impairments of neurocognitive function and subjective feelings of high did emerge despite low levels of JWH‐018 in serum. Higher doses are needed to obtain a more representative risk profile of JWH‐018. </p> </div>

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          Specific impairments of planning.

          T Shallice (1982)
          An information-processing model is outlined that predicts that performance on non-routine tasks can be impaired independently of performance on routine tasks. The model is related to views on frontal lobe functions, particularly those of Luria. Two methods of obtaining more rigorous tests of the model are discussed. One makes use of ideas from artificial intelligence to derive a task heavily loaded on planning abilities. A group of patients with left anterior lesions has a specific deficit on the task. Subsidiary investigations support the inference that this is a planning impairment.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS).

            The purpose of this study was to develop an instrument for the measurement of present-state dissociative symptoms, the Clinician Administered Dissociative States Scale (CADSS). Reported here are interrater reliability and internal consistency of the CADSS, validity as assessed by comparisons with other instruments for the assessment of dissociation, and sensitivity of the CADSS to discriminate patients with dissociative disorders from patients with other psychiatric disorders and healthy subjects. Initial analyses indicated good interrater reliability and construct validity for the CADSS. Scores on the CADSS discriminated patients with dissociative disorders from the other groups.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?

                Bookmark

                Author and article information

                Journal
                British Journal of Pharmacology
                British Journal of Pharmacology
                Wiley-Blackwell
                00071188
                January 2018
                January 29 2018
                : 175
                : 1
                : 18-28
                Article
                10.1111/bph.14066
                5740243
                29164599
                3e499af2-e3a0-4959-86eb-4d8b18d6a488
                © 2018

                http://doi.wiley.com/10.1002/tdm_license_1.1

                History

                Comments

                Comment on this article